MedPath

The British Heart Foundation SENIOR-RITA Trial

Not Applicable
Active, not recruiting
Conditions
NSTEMI - Non-ST Segment Elevation MI
Interventions
Procedure: Coronary Angiography
Other: Optimal Medical Therapy
Procedure: Coronary revascularisation
Registration Number
NCT03052036
Lead Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Brief Summary

SENIOR-RITA is a multicentre prospective open-label trial randomizing patients presenting with type 1 NSTEMI aged ≥75 years between invasive and conservative treatment strategies, to compare time from randomisation to cardiovascular death or non-fatal MI

Detailed Description

The population is getting older and heart artery disease is the biggest killer in the UK. Over recent years, there have been improvements in medications and technologies to treat it, but these have been primarily tested in younger patients. Previous research studies suggest that older patients (75 years and over) are not well represented in clinical research and these patients in particular those that are frail and those with co-morbidities are less likely to receive advanced medications and medical procedures. The current study will enrol patients 75 years and over, presenting with a heart attack. If patients agree to participate, they will be randomly allocated to one of two treatment groups. In the first group, patients will receive the latest medications recommended in heart attack. In the second group, in addition to these medications, patients will have coronary angiography. This will show whether they have any blockages in heart arteries. If appropriate, coronary revascularisation by percutaneous coronary intervention (PCI) commonly known as coronary angioplasty or coronary artery bypass grafting, sometimes called CABG (a surgical procedure in which a blood vessel from the leg, arm or chest is used to bypass a narrowed section of a coronary artery) will be carried out. During the trial, frailty scores, cognition measures, co-morbidity indices, questionnaires on quality of life, NHS and personal social services utilization will be collected from the participant and in addition proxy quality of life information will be collected from the participant's carers. Investigators will evaluate which one of the two treatment groups will do better and live longer. Investigators will also collect information on their quality of life and frailty measures for a 5 year period. The trial hopes to recruit 2300 patients from approximately 30 centres across the UK.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
1518
Inclusion Criteria
  • Aged ≥ 75 years
  • Type 1 NSTEMI during index hospitalisation
Exclusion Criteria
  • Patients presenting with STEMI or unstable angina
  • Patients with cardiogenic shock
  • Patients with known life expectancy <1 year
  • Patients in whom neither the patient nor the consultee are able and willing to provide written informed consent
  • Previous inclusion in the BHF SENIOR-RITA trial
  • Inability to undergo invasive coronary angiography, such as no vascular access site, or absolute contraindication to coronary revascularisation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Invasive TreatmentCoronary AngiographyCoronary angiography with a view to coronary revascularisation
Invasive TreatmentCoronary revascularisationCoronary angiography with a view to coronary revascularisation
Optimal Medical TherapyOptimal Medical TherapyPatients to be treated with guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE inhibitors, betabloackers
Invasive TreatmentOptimal Medical TherapyCoronary angiography with a view to coronary revascularisation
Primary Outcome Measures
NameTimeMethod
Time to cardiovascular death or non-fatal MI (defined by the fourth universal definition) from randomizationUp to 5 years

To determine the impact of a routine invasive strategy on cardiovascular death and non-fatal myocardial infarction (MI) compared with a conservative treatment strategy in older patients (≥75 years) with NSTEMI.

Secondary Outcome Measures
NameTimeMethod
Incremental cost per QALY gained at 1 yearUp to 5 years
Renal replacement therapyWithin 7 days of invasive care

Need for renal replacement therapy

Recurrent myocardial infarctionUp to 5 years
Hospitalisation for heart failureUp to 5 years
Urgent coronary revascularisationUp to 5 years
Recurrent hospitalisation for myocardial infarctionUp to 5 years
StrokeUp to 5 years
Length of time spent at homeUp to 5 years
BleedingUp to 1 year

Bleeding according to BARC Criteria

All cause, cardiovascular and non-cardiovascular death ratesUp to 5 years
Fried and Rockwood frailty scoresUp to 5 years
Procedural complicationsWithin 7 days of invasive care

Perforation, myocardial infarction (Type 4a), coronary dissection, TIA, Death in Cath Lab, Aortic dissection

Quality of Life using EQ-5D-5L and quality adjusted life years (QALY)Up to 5 years

Quality of life will be measured using the EQ-5D-5L instrument\[REF: The EuroQol Group (1990). EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16(3):199-208html \] (paper and telephone versions), with the results for each participant converted into quality-adjusted life-years (QALYs) using the area under the curve approach, a standard methodology for this process,\[REF: Drummond MOB, B; Stoddart, G; Torrance, G. . Methods for the economic evaluation of Health Care Programmes: Oxford University Press 2005.\] with the responses to the EQ-5D-5L scored using the appropriate value set for the United Kingdom, which is expected to be available by the time of the analysis. REF: Office for Health Economics. New OHE Publications: An EQ-5D-5L Value Set for England. Available at: https://www.ohe.org/news/new-ohe-publications-eq-5d-5l-value-set-england. Accessed February 03 2017\]

Costs to the NHS and personal social servicesUp to 5 years
25% increase in serum creatinine concentrationWithin 7 days of invasive care

25% increase in serum creatinine concentration from baseline (hospitalisation)

Trial Locations

Locations (40)

Pinderfields General Hospital

🇬🇧

Wakefield, West Yorkshire, United Kingdom

Basildon & Thurrock University Hospitals NHS Foundation Trust

🇬🇧

Basildon, United Kingdom

Aberdeen Royal Infirmary

🇬🇧

Aberdeen, United Kingdom

Cumberland Infirmary, North Cumbria University Hospitals NHS Trust

🇬🇧

Carlisle, United Kingdom

Bradford Teaching Hospitals NHS Foundation Trust

🇬🇧

Bradford, United Kingdom

Chesterfield Royal Hospital NHS Foundation Trust

🇬🇧

Chesterfield, United Kingdom

Broomfield Hospital, Mid Essex Hospitals NHS Trust

🇬🇧

Broomfield, United Kingdom

St Helier Hospital, Epsom & St Helier University Hospitals NHS Trust

🇬🇧

Carshalton, United Kingdom

Royal Derby Hospital, Derby Teaching Hospitals NHS Foundation Trust

🇬🇧

Derby,, United Kingdom

County Durham & Darlington NHS Foundation Trust

🇬🇧

Darlington, United Kingdom

Ninewells Hospital, NHS Tayside

🇬🇧

Dundee, United Kingdom

Lanarkshire East Kilbride NHS Foundation Trust

🇬🇧

East Kilbride, United Kingdom

Royal Infirmary of Edinburgh

🇬🇧

Edinburgh, United Kingdom

East Sussex NHS Healthcare Trust

🇬🇧

Eastbourne, United Kingdom

Royal Alexandra Hospital

🇬🇧

Glasgow, United Kingdom

Gateshead Hospitals NHS Foundation Trust

🇬🇧

Gateshead, United Kingdom

NHS Ayrshire & Arran

🇬🇧

Kilmarnock, United Kingdom

Leeds General Infirmary

🇬🇧

Leeds, United Kingdom

North Tees and Hartlepool Foundation Trust

🇬🇧

Hartlepool, United Kingdom

Hammersmith Hospital, Imperial College Healthcare NHS Trust

🇬🇧

London, United Kingdom

London Royal Free, Royal Free London NHS Foundation Trust

🇬🇧

London, United Kingdom

United Lincolnshire Healthcare Trust

🇬🇧

Lincoln, United Kingdom

Chelsea and Westminster

🇬🇧

London, United Kingdom

Wythenshawe Hospital, University Hospital of South Manchester NHS Foundation Trust

🇬🇧

Manchester, United Kingdom

Borders General Hospital

🇬🇧

Melrose, United Kingdom

South Tees NHS Foundation Trust

🇬🇧

Middlesbrough, United Kingdom

The Newcastle Upon Tyne Hospital NHS Foundation Trust

🇬🇧

Newcastle upon Tyne, United Kingdom

Plymouth Hospital, Plymouth Hospitals NHS Trust

🇬🇧

Plymouth, United Kingdom

Pennine Acute Hospitals NHS Trust

🇬🇧

Oldham, United Kingdom

Royal Berkshire Hospital, Royal Berkshire Foundation NHS Trust

🇬🇧

Reading, United Kingdom

East Surrey Hospital, Surrey & Sussex NHS Trust

🇬🇧

Redhill, United Kingdom

Salford Royal NHS Foundation Trust

🇬🇧

Salford, United Kingdom

South Tyneside NHS Foundation Trust

🇬🇧

South Shields, United Kingdom

Torbay Hospital, Torbay & South Devon NHS Foundation Trust

🇬🇧

Torquay, United Kingdom

City Hospitals Sunderland NHS Foundation Trust

🇬🇧

Sunderland, United Kingdom

The York Hospital, York Teaching Hospital NHS Foundation Trust

🇬🇧

York, United Kingdom

Queen Elizabeth University Hospital

🇬🇧

Glasgow, United Kingdom

Sheffield Teaching Hospitals NHS Foundation Trust

🇬🇧

Sheffield, United Kingdom

Northumbria Healthcare NHS Foundation Trust

🇬🇧

North Shields, United Kingdom

Blackpool Teaching Hospitals NHS Foundation Trust

🇬🇧

Blackpool, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath